RESUMO
Objective To explore the effects of pyridoxal kinase (PDXK) on the proliferation of serous ovarian cancer (SOC) HEY cells, and analyze its relationship with clinicopathological features of patients. Methods The expression of PDXK in normal ovarian IOSE80 cells and ovarian cancer 3AO, A2780, OVCAR3, ES-2, HEY cells were detected by real-time quantitative PCR and Western blotting. After the knockdown of PDXK in ovarian cancer HEY cells, CCK-8 assay was used to detect cell proliferation and flow cytometry was used to detect cell cycle. Furthermore, we detected the expression of PDXK in normal ovarian epithelial tissues and SOC tissues by immunohistochemistry, and analyzed its correlation with clinicopathological features and prognosis. Results The expression of PDXK in ovarian cancer cell lines was higher than that in normal ovarian cell lines. Knockdown of PDXK attenuated the proliferation and blocked the transition of G1/S phase in HEY cells. PDXK expression was higher in SOC tissues than in normal ovarian tissues. Higher PDXK expression was positively correlated with advanced FIGO stage, poor differentiation and higher CA125 level. Besides, patients with higher PDXK expression had shorter progression-free-survival (PFS). Conclusion PDXK may promote SOC cell proliferation and be associated with a poor prognosis.
